Patents by Inventor Jeffery Claude Pelletier
Jeffery Claude Pelletier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240358685Abstract: Disclosed are acyl benzo[d]thiazol-2-amines having a structure according to formula (I): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof. The compounds may be useful for the treatment of various diseases including, for example, neurological disorders such as amyotrophic lateral sclerosis, bipolar disorder, treatment resistant and major depression, general anxiety disorder, and cancers such as melanoma, breast cancer, brain cancer, and prostate cancer.Type: ApplicationFiled: July 8, 2024Publication date: October 31, 2024Inventors: Jeffery Claude PELLETIER, Allen B. REITZ, Jay Edward WROBEL
-
Patent number: 12029731Abstract: Disclosed are acyl benzo[d]thiazol-2-amines having a structure according to formula (I): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof. The compounds may be useful for the treatment of various diseases including, for example, neurological disorders such as amyotrophic lateral sclerosis, bipolar disorder, treatment resistant and major depression, general anxiety disorder, and cancers such as melanoma, breast cancer, brain cancer, and prostate cancer.Type: GrantFiled: August 10, 2017Date of Patent: July 9, 2024Assignee: Biohaven Therapeutics Ltd.Inventors: Jeffery Claude Pelletier, Allen B. Reitz, Jay Edward Wrobel
-
Patent number: 12005047Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: July 29, 2023Date of Patent: June 11, 2024Assignee: Biohaven Therapeutics Ltd.Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20240091205Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: July 29, 2023Publication date: March 21, 2024Inventors: Jay Edward WROBEL, Allen B. REITZ, Jeffery Claude PELLETIER, Garry Robert SMITH, Haiyan BIAN
-
Patent number: 11911369Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: May 4, 2020Date of Patent: February 27, 2024Assignee: Biohaven Therapeutics Ltd.Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20230381149Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: July 29, 2023Publication date: November 30, 2023Inventors: Jay Edward WROBEL, Allen B. REITZ, Jeffery Claude PELLETIER, Garry Robert SMITH, Haiyan BIAN
-
Publication number: 20230381150Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: July 29, 2023Publication date: November 30, 2023Inventors: Jay Edward WROBEL, Allen B. REITZ, Jeffery Claude PELLETIER, Garry Robert SMITH, Haiyan BIAN
-
Publication number: 20230017637Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: July 5, 2021Publication date: January 19, 2023Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20220396555Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: May 4, 2020Publication date: December 15, 2022Applicant: Biohaven Therapeutics Ltd.Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Patent number: 11358935Abstract: Pharmaceutical compositions of the invention include substituted Lanicemine prodrugs useful for the treatment of conditions associated with dysregulation of NMDA receptor activity such as depression and depressive disorders through the release of Lanicemine, Prodrugs of Lanicemine have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release Lanicemine in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: November 22, 2017Date of Patent: June 14, 2022Assignee: Biohaven Pharmaceutical Holding Company Ltd.Inventors: Allen B. Reitz, Jeffery Claude Pelletier
-
Patent number: 11052070Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: November 20, 2019Date of Patent: July 6, 2021Assignee: Biohaven Therapeutics Ltd.Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20200299238Abstract: Pharmaceutical compositions of the invention include substituted Lanicemine prodrugs useful for the treatment of conditions associated with dysregulation of NMDA receptor activity such as depression and depressive disorders through the release of Lanicemine, Prodrugs of Lanicemine have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release Lanicemine in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: November 22, 2017Publication date: September 24, 2020Inventors: Allen B. Reitz, Jeffery Claude Pelletier
-
Publication number: 20200157069Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: January 21, 2020Publication date: May 21, 2020Inventors: Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffery Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
-
Patent number: 10639298Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: February 26, 2016Date of Patent: May 5, 2020Assignee: Biohaven Therapeutics Ltd.Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20200085794Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: November 20, 2019Publication date: March 19, 2020Applicant: Biohaven Therapeutics Ltd.Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Patent number: 10562870Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: August 4, 2017Date of Patent: February 18, 2020Assignee: Biohaven Pharmaceutical Holding Company Ltd.Inventors: Garry Robert Smith, Allen B. Reitz, Mark Mcdonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffery Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
-
Patent number: 10485791Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: GrantFiled: February 26, 2016Date of Patent: November 26, 2019Assignee: Biohaven Therapeutics Ltd.Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
-
Publication number: 20190209532Abstract: Disclosed are acyl benzo[d]thiazol-2-amines having a structure according to formula (I): including enantiomers, diastereomers, hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof. The compounds may be useful for the treatment of various diseases including, for example, neurological disorders such as amyotrophic lateral sclerosis, bipolar disorder, treatment resistant and major depression, general anxiety disorder, and cancers such as melanoma, breast cancer, brain cancer, and prostate cancer.Type: ApplicationFiled: August 10, 2017Publication date: July 11, 2019Inventors: Jeffery Claude PELLETIER, Allen B. REITZ, Jay Edward WROBEL
-
Publication number: 20170334870Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.Type: ApplicationFiled: August 4, 2017Publication date: November 23, 2017Inventors: Garry Robert Smith, Allen B. Reitz, Mark Mcdonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffery Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
